Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026
Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026
Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026
Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026
Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Policy / Regulatory

China’s NMPA Updates Rules for Administrative Penalty Discretions in Drug Supervision

Fineline Cube Feb 27, 2024

The National Medical Products Administration (NMPA) has issued the “Rules for the Application of Administrative...

Company Drug

AstraZeneca’s Fasenra Matches Nucala in EGPA Trial and Shows Steroid Reduction Benefits

Fineline Cube Feb 27, 2024

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has presented results from a Phase III trial...

Company Drug

BeiGene’s Tislelizumab Receives CHMP Recommendation for Three NSCLC Indications in Europe

Fineline Cube Feb 27, 2024

BeiGene (NASDAQ: BGNE) has announced that the European Medicines Agency’s Committee for Medicinal Products for...

Company Deals

Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond

Fineline Cube Feb 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196,HKG: 2196), a Chinese pharmaceutical heavyweight, has entered...

Company Drug

Everest Medicines Gets CDE Approval for Global Phase IIb Study of Zetomipzomib in Lupus Nephritis

Fineline Cube Feb 27, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira

Fineline Cube Feb 27, 2024

The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO)...

Company

BeiGene Reports Record Revenues and Rapid Growth in Q4 and Full Year 2023 with Continued Expansion

Fineline Cube Feb 27, 2024

BeiGene (NASDAQ: BGNE), a China-based biopharmaceutical company, has presented its financial results for the fourth...

Company Deals

Novo Nordisk Partners with Neomorph to Target Undruggable Diseases with Molecular Glue Degraders

Fineline Cube Feb 27, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has entered into a partnership with US-based Neomorph...

Company

AstraZeneca Expands Global Footprint with Shanghai Strategic Center

Fineline Cube Feb 27, 2024

AstraZeneca (AZ, NASDAQ: AZN) has declared that Shanghai is now its fifth global strategic center,...

Company Deals

Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development

Fineline Cube Feb 26, 2024

Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co.,...

Company Deals Drug

Kelun-Biotech Launches Clinical Trials for SKB264, Triggering $75 Million Milestone Payment from MSD

Fineline Cube Feb 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) has announced the initiation of clinical trials for...

Company Drug

AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics

Fineline Cube Feb 26, 2024

AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA...

Company Deals

b-ONE Ortho Partners with THINK Surgical to Expand MOBIO Knee System in U.S. Market

Fineline Cube Feb 26, 2024

b-ONE Ortho Corp., a developer of artificial joint replacements with operations in the U.S. and...

Company Deals

CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System

Fineline Cube Feb 26, 2024

CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a...

Company Deals

Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal

Fineline Cube Feb 26, 2024

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation...

Policy / Regulatory

Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area

Fineline Cube Feb 26, 2024

The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch...

Company Deals Digital

Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations

Fineline Cube Feb 26, 2024

Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees...

Company Drug

Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension

Fineline Cube Feb 26, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...

Company Deals

Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries

Fineline Cube Feb 26, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...

Policy / Regulatory

Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits

Fineline Cube Feb 26, 2024

The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...

Posts pagination

1 … 404 405 406 … 672

Recent updates

  • Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing
  • TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC
  • Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
  • Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.